泽璟制药：注射用ZGGS34临床试验申请获得美国食品药品监督管理局批准

Core Viewpoint - Zai Jiang Pharmaceutical has received FDA approval for its investigational product ZGGS34, aimed at treating advanced solid tumors, which could enhance its market position and revenue potential [2] Company Summary - Zai Jiang Pharmaceutical's revenue composition for the year 2024 is heavily weighted towards pharmaceutical manufacturing, accounting for 99.73% of total revenue, with other business activities contributing only 0.27% [2]